Reliability assessment of methylthioadenosine phosphorylase immunohistochemistry as a surrogate biomarker for CDKN2A homozygous deletion in adult-type IDH-mutant diffuse gliomas.
| Autor: | Gundogdu F; Department of Pathology, Hacettepe University, Ankara, Turkey., Babaoglu B; Department of Pathology, Hacettepe University, Ankara, Turkey., Soylemezoglu F; Department of Pathology, Hacettepe University, Ankara, Turkey. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of neuropathology and experimental neurology [J Neuropathol Exp Neurol] 2024 Jan 19; Vol. 83 (2), pp. 107-114. |
| DOI: | 10.1093/jnen/nlad109 |
| Abstrakt: | According to the 2021 World Health Organization classification of brain tumors, astrocytomas containing a CDKN2A/B homozygous deletion (HD) are designated as grade 4 even when no microvascular proliferation and/or necrosis is present. In this study, we aimed to investigate the relationship between CDKN2A HD and loss of methylthioadenosine phosphorylase (MTAP) expression in adult-type IDH-mutant gliomas and to assess the sensitivity and specificity of MTAP immunohistochemistry (IHC) along with interobserver agreement as a surrogate biomarker for CDKN2A HD. Eighty-eight astrocytomas and 71 oligodendrogliomas cases that were diagnosed between 2014 and 2021 at Hacettepe University were selected and tissue microarrays were conducted to perform CDKN2A fluorescence in situ hybridization and MTAP IHC. Twenty-five (15.7%) cases harbored CDKN2A HD. MTAP loss was detected in 28 (15.7%) cases by the first observer and 27 (17%) cases by the second observer. The sensitivity and specificity of MTAP were calculated as 88% and 95.52%-96.27% for 2 observers. A very good/perfect agreement was noted between the observers (Cohen kappa coefficient = 0.938). Intratumoral heterogeneity was observed in 4 cases. MTAP IHC was found to be a reliable surrogate biomarker as a possible alternative to CDKN2A HD identification with a high sensitivity and specificity along with high interobserver agreement. (© The Author(s) 2023. Published by Oxford University Press on behalf of American Association of Neuropathologists, Inc.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|